-
1
Attenuated T cell responses to a high-potency ligand in vivo.
Published 2010-09-01Get full text
Article -
2
-
3
Tumor-Expressed IDO Recruits and Activates MDSCs in a Treg-Dependent Manner
Published 2015-10-01Get full text
Article -
4
-
5
-
6
-
7
-
8
-
9
-
10
Pilot study of Tremelimumab with and without cryoablation in patients with metastatic renal cell carcinoma
Published 2021-11-01Get full text
Article -
11
HSP90 inhibition enhances cancer immunotherapy by upregulating interferon response genes
Published 2017-09-01Get full text
Article -
12
Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity
Published 2016-08-01Get full text
Article -
13
-
14
-
15
-
16
Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma
Published 2017-04-01Get full text
Article -
17
Immunological targets for cancer therapy: new recognition
Published 2018-11-01“…Blocking cancer progression by eliminating brakes on immune effector cells in the tumor environment has jointly earned James P Allison, PhD (Department of Immunology, MD Anderson Cancer Center, University of Texas, Houston, TX, USA) and Tasuku Honjo, MD, PhD (Graduate School of Medicine, Kyoto University, Kyoto, Japan) the Nobel Prize in Physiology or Medicine in 2018. …”
Get full text
Article -
18
Immune checkpoint blockade therapy: The 2014 Tang prize in biopharmaceutical science
Published 2015-02-01“…The first Tang Prize for Biopharmaceutical Science has been awarded to Prof. James P. Allison and Prof. Tasuku Honjo for their contributions leading to an entirely new way to treat cancer by blocking the molecules cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and programmed cell death protein 1 (PD-1) that turn off immune response. …”
Get full text
Article -
19
Systems glycobiology for discovering drug targets, biomarkers, and rational designs for glyco-immunotherapy
Published 2021-06-01“…In 2018, two pioneer immunotherapy innovators, Tasuku Honjo and James P. Allison, were awarded the Nobel Prize for their landmark cancer immunotherapy work regarding “cancer therapy by inhibition of negative immune regulation” –CTLA4 and PD-1 immune checkpoints. …”
Get full text
Article -
20
Top 100 Most Cited Publications on CTLA-4 Molecule in Cancer Research: A Bibliometric Analysis
Published 2023-01-01“…There were 1192 authors and the author with the highest number of papers was the Nobel Prize winner, Professor James P. Allison (17 papers; 8700 citations). CTLA-4 blockade was the most frequent keyword (42.1%), followed by metastatic melanoma (4.26%). …”
Get full text
Article